Jerome Stevens Patent-Cliff Exposure & CMS Drug Spending Portfolio

Jerome Stevens (US): 2 reconciled FDA prescription therapies, $5.9M 2024 CMS Part D & Medicaid spend, and 13 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$5.9M
2024 Medicare Part D Spend$4.4M
2024 Medicaid Spend$1.5M
California HCAI SB 17 Filings13 WAC filings (max 30.3% 2-yr change)